You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
Abbvie to continue manufacturing component for lymphoma drug
State Of Singapore Online Video Subscription
Power Forecast Briefing: Capacity Shortfalls to Test the Renewable Energy Transition
Episode 43 - More Change, M&A On Horizon For Equity Research Industry
Cable Nets Struggle With Little Revenue Growth Expanding Programming Budgets
Seattle Genetics Inc. asked AbbVie Inc. to continue manufacturing a component for its Adcetris drug.
The companies extended a development and supply agreement under which AbbVie will manufacture the anti-CD30 monoclonal antibody through Dec. 31, 2025, as opposed to Aug. 22, 2021, previously. The contract will automatically renew unless terminated by either party.
Adcetris is used for the treatment of classical Hodgkin lymphoma, a form of cancer that affects the immune system.